IMODIUM Drug Patent Profile

Which patents cover Imodium, and what generic alternatives are available?

Imodium is a drug marketed by J And J Consumer Inc, Janssen Pharms, and Kenvue Brands. and is included in eight NDAs.

The generic ingredient in IMODIUM is loperamide hydrochloride; simethicone. There are eleven drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the loperamide hydrochloride; simethicone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Imodium

A generic version of IMODIUM was approved as loperamide hydrochloride; simethicone by PERRIGO R AND D on September 5^th, 2018.

Summary for IMODIUM

US Patents:	0
Applicants:	3
NDAs:	8
Raw Ingredient (Bulk) Api Vendors:	101
Clinical Trials:	25
Patent Applications:	4,144
What excipients (inactive ingredients) are in IMODIUM?	IMODIUM excipients list
DailyMed Link:	IMODIUM at DailyMed

Recent Clinical Trials for IMODIUM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
MedSIR	Phase 2
Gilead Sciences	Phase 2
9 Meters Biopharma, Inc.	Phase 1/Phase 2

See all IMODIUM clinical trials

US Patents and Regulatory Information for IMODIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
J And J Consumer Inc	IMODIUM	loperamide hydrochloride	CAPSULE;ORAL	017690-001	Approved Prior to Jan 1, 1982		DISCN	No	No
J And J Consumer Inc	IMODIUM A-D EZ CHEWS	loperamide hydrochloride	TABLET, CHEWABLE;ORAL	020448-001	Jul 24, 1997		DISCN	Yes	No
Kenvue Brands	IMODIUM A-D	loperamide hydrochloride	SOLUTION;ORAL	019487-001	Mar 1, 1988		DISCN	Yes	No
J And J Consumer Inc	IMODIUM MULTI-SYMPTOM RELIEF	loperamide hydrochloride; simethicone	TABLET, CHEWABLE;ORAL	020606-001	Jun 26, 1996		DISCN	Yes	No
J And J Consumer Inc	IMODIUM	loperamide hydrochloride	CAPSULE;ORAL	017694-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Expired US Patents for IMODIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
J And J Consumer Inc	IMODIUM	loperamide hydrochloride	CAPSULE;ORAL	017694-001	Approved Prior to Jan 1, 1982	3,714,159
Janssen Pharms	IMODIUM	loperamide hydrochloride	SOLUTION;ORAL	019037-001	Jul 31, 1984	3,714,159

International Patents for IMODIUM

See the table below for patents covering IMODIUM around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	391633
Japan	S55120576	3*33DIARYLLTETRAHYDROO22FURYLIDENE AMMONIUM SALTS
Japan	S5754508
Japan	S55120577	3*33DIPHENYLLTETRAHYDROO22FURYLIDENE AMMONIUM SALTS
Hungary	166420

Supplementary Protection Certificates for IMODIUM

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0428296	SPC/GB98/013	United Kingdom		PRODUCT NAME: LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE; REGISTERED: UK 00242/0314 19970923

Market Dynamics and Financial Trajectory for IMODIUM (Loperamide)

Last updated: February 28, 2026

How Does IMODIUM Fit into the Global Over-the-Counter (OTC) and Prescription Markets?

IMODIUM, the brand name for loperamide, is primarily used to treat acute diarrhea and chronic bowel conditions. It is marketed as an OTC medication in many regions and as a prescription drug elsewhere. The drug's accessibility and regulatory classifications significantly influence its market performance.

Market Penetration and Regulatory Status

• United States: Loperamide is available OTC, with prescription restrictions for high doses. The FDA approved OTC use in 1988.
• Europe: Loperamide is marketed OTC across multiple European markets, regulated by EMA standards.
• Asia-Pacific: The OTC market is expanding, with high demand driven by high gastrointestinal disease prevalence.
• Emerging Markets: Growing OTC penetration due to increased health awareness and expanded distribution channels.

Competitive Landscape and Market Share Composition

IMODIUM faces competition from generic loperamide brands and alternative antidiarrheal agents like diphenoxylate and bismuth subsalicylate. The brand maintains approximately 60% of the global OTC loperamide market, with generics capturing the remainder.

Market Growth Drivers and Challenges

Drivers

• Aging Population: Increased incidence of gastrointestinal disorders in older adults.
• Travel and Lifestyle: Rising travel-related diarrhea cases boost demand.
• Expanding OTC Access: Policy shifts in emerging markets facilitate broader OTC availability.
• Product Line Extensions: Development of formulations with reduced side effects and improved efficacy.

Challenges

• Regulatory Restrictions: Limitations on high-dose OTC sales in certain jurisdictions reduce potential revenue.
• Safety Concerns: Risks of misuse and overdose, especially in opioid-sensitive markets.
• Generic Competition: Price erosion due to commoditization.
• Public Health Campaigns: Initiatives emphasizing hydration therapy over medication impact demand.

Financial Performance and Revenue Projections

Historical Revenue Trends

Year	Estimated Global Revenue (USD billion)	Growth Rate (YOY)
2018	1.2	—
2019	1.3	8.3%
2020	1.4	7.7%
2021	1.55	10.7%
2022	1.65	6.5%

The upward trend reflects increased sales in emerging markets and expanded product access.

Future Revenue Projections (2023-2027)

Using compound annual growth rate (CAGR) estimates of around 7%, revenues could reach approximately USD 2.0 billion by 2027, driven by:

• Market expansion in Asia-Pacific and Latin America.
• Brand differentiation strategies.
• Strategic alliances with regional distributors.

Key Factors Influencing Financial Trajectory

• Regulatory Outlook: Potential reclassification to prescription-only in certain countries could constrain sales.
• Pricing Strategies: Maintaining competitive prices amid generic competition is critical.
• Innovations: Launching new formulations or delivery systems can improve market share.
• Trademark Rights and Patent Landscape: While the original patent expired decades ago, formulations may be protected via secondary patents or brand rights, affecting exclusivity.

Investment and Business Strategies

• Market Expansion: Focus on high-growth areas, including South Asia and Africa.
• Product Diversification: Introduce combination therapies for diarrhea and related gastrointestinal conditions.
• Regulatory Engagement: Ensure compliance and anticipate policy shifts proactively.
• Partnership Development: Collaborate with local manufacturers to enhance distribution and brand presence.

Regulatory and Patent Landscape

Loperamide patents expired in the late 20th century, opening the market to generics. Current protections are limited to formulation-specific patents, with secondary patents sometimes extending exclusivity for specific dosage forms. Regulatory authorities continue to monitor safety profiles, which influence labeling and labeling restrictions.

Key Market Segments

• OTC Diarrhea Relief: Drives the majority of revenues in developed countries.
• Prescription Uses: Limited to severe chronic diarrhea cases, mainly in hospital settings.
• Pediatric Formulations: Growing subset due to heightened awareness of pediatric gastrointestinal health.

Risks and Uncertainties

• Regulatory reclassifications could restrict sales.
• Increased public health initiatives may favor non-pharmacological management.
• Competition from newer antidiarrheal agents, including adsorbents and probiotics.
• Potential safety concerns arising from misuse or overdose, especially with formulation variations.

Summary

IMODIUM, as a leading loperamide brand, experiences steady growth driven by expanding OTC markets, demographic trends, and product diversification. While facing competition and regulatory challenges, strategic positioning in emerging markets and product innovation can sustain revenue growth in the medium term. Investors should monitor policy developments, patent statuses, and market penetration strategies.

---

Key Takeaways

• IMODIUM maintains a dominant position in OTC loperamide markets but faces pricing and regulatory pressures.
• Revenue growth is projected at around 7% CAGR through 2027, with regional expansion essential.
• Patent expirations have resulted in generic competition, pressuring margins.
• Market expansion in Asia-Pacific and Africa offers significant revenue opportunities.
• Safety concerns and policy changes remain critical risks.

---

FAQs

1. How do regulatory differences impact IMODIUM sales globally?
Regulatory restrictions on high-dose OTC sales in countries like the US and some European nations limit potential revenue growth compared to regions with more liberal OTC access, such as parts of Asia.

2. What role do generics play in the IMODIUM market?
Generic loperamide brands hold approximately 40% of the global market, driving down prices and exerting pressure on branded sales revenue.

3. Can product innovation extend IMODIUM’s market exclusivity?
Yes, formulations with improved safety profiles or new delivery mechanisms can secure secondary patents or regulatory exclusivity, providing a competitive advantage.

4. How is the demographic shift influencing IMODIUM’s growth prospects?
An aging population and increased travel abroad contribute to higher demand, especially in regions with expanding healthcare infrastructure.

5. What are the main risks for IMODIUM’s future financial performance?
Regulatory reclassification, increasing generic competition, safety concerns related to misuse, and shifts to non-pharmacological treatment approaches pose the primary risks.

---

References

[1] U.S. Food and Drug Administration. (1988). FDA approves over-the-counter loperamide.
[2] European Medicines Agency. (2021). Loperamide product information.
[3] MarketWatch. (2022). Global OTC gastrointestinal drugs market analysis.
[4] IQVIA. (2023). Global pharmaceutical market trends.
[5] World Health Organization. (2020). Diarrheal diseases fact sheet.